Lyell Immunopharma (NASDAQ:LYEL) Posts Quarterly Earnings Results, Beats Expectations By $0.68 EPS

Lyell Immunopharma (NASDAQ:LYEL) posted its quarterly earnings data on Wednesday. The company reported ($2.13) EPS for the quarter, beating the consensus estimate of ($2.81) by $0.68, FiscalAI reports. Lyell Immunopharma had a negative return on equity of 85.58% and a negative net margin of 552,328.31%.The firm had revenue of $0.02 million during the quarter.

Lyell Immunopharma Trading Up 2.2%

Lyell Immunopharma stock traded up $0.38 during trading on Wednesday, hitting $17.63. The company had a trading volume of 12,957 shares, compared to its average volume of 72,090. The stock has a market cap of $338.67 million, a price-to-earnings ratio of -0.73 and a beta of -0.07. Lyell Immunopharma has a 1-year low of $7.65 and a 1-year high of $23.40. The company’s 50 day simple moving average is $15.54 and its 200-day simple moving average is $11.84.

Institutional Investors Weigh In On Lyell Immunopharma

Several institutional investors and hedge funds have recently modified their holdings of LYEL. Acadian Asset Management LLC lifted its stake in Lyell Immunopharma by 204.2% during the 1st quarter. Acadian Asset Management LLC now owns 660,899 shares of the company’s stock worth $354,000 after acquiring an additional 443,614 shares in the last quarter. Vanguard Group Inc. increased its stake in Lyell Immunopharma by 76.0% during the third quarter. Vanguard Group Inc. now owns 779,004 shares of the company’s stock worth $12,651,000 after purchasing an additional 336,378 shares during the period. AQR Capital Management LLC lifted its position in shares of Lyell Immunopharma by 773.5% during the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock worth $94,000 after purchasing an additional 154,327 shares in the last quarter. Orbimed Advisors LLC purchased a new position in shares of Lyell Immunopharma in the second quarter valued at approximately $457,000. Finally, Walleye Capital LLC purchased a new position in shares of Lyell Immunopharma in the second quarter valued at approximately $258,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on LYEL. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Wednesday, October 8th. Wall Street Zen raised Lyell Immunopharma from a “sell” rating to a “hold” rating in a report on Monday, September 1st. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average target price of $10.00.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.